Yamashita K, Ohta H, Uchida S, Shigematsu K, Ohkubo T, Niwa M, Ozaki M
Department of Pharmacology 2, Nagasaki University School of Medicine, Japan.
J Pharmacobiodyn. 1990 Jan;13(1):64-9. doi: 10.1248/bpb1978.13.64.
The preventive effects of carteolol, a beta-adrenoceptor antagonist, on secondary lesions were pathophysiologically examined in stroke-prone spontaneously hypertensive rats (SHRSP) from 8 to 30 weeks of age. Carteolol was added to the drinking water in doses of 0.005% (8 to 18 weeks of age) to 0.01% (19 to 30 weeks of age) (3.8 and 6.0 mg/kg/d, respectively). These animals gained significantly more weight than the untreated control SHRSP, and their heart rate reduced from 14 weeks of age. Suppression of blood pressure rise was not definite, however, histology revealed prevention of the development or aggravation of secondary hypertension-related lesions, such as myocardial fibrosis, proliferative arteriolitis, necrotic arteriolitis and renal glomerular lesions. A decrease in non-esterified fatty acids in the serum was evident. Thus, carteolol has cardiac as well as renal protective effects, in the SHRSP.
在8至30周龄的易中风自发性高血压大鼠(SHRSP)中,从病理生理学角度研究了β肾上腺素受体拮抗剂卡替洛尔对继发性病变的预防作用。卡替洛尔以0.005%(8至18周龄)至0.01%(19至30周龄)的剂量添加到饮用水中(分别为3.8和6.0毫克/千克/天)。这些动物的体重显著高于未治疗的对照SHRSP,并且从14周龄起心率降低。然而,血压升高的抑制并不确定,组织学显示预防了继发性高血压相关病变的发展或加重,如心肌纤维化、增生性小动脉炎、坏死性小动脉炎和肾小球病变。血清中非酯化脂肪酸明显减少。因此,在SHRSP中,卡替洛尔具有心脏和肾脏保护作用。